Verastem Inc (VSTM)

Jan 25, 2026

Breakout Zone: What is the Moat Score of Verastem IncJuly 2025 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn

Jan 25, 2026

Jan 17, 2026

Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up - TipRanks

Jan 17, 2026

Jan 16, 2026

Retail Trends: Does Verastem Inc have a competitive edgeJuly 2025 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn

Jan 16, 2026

Jan 16, 2026

Have Verastem Insiders Been Selling Stock? - simplywall.st

Jan 16, 2026

Jan 16, 2026

CEO Change: Is Icahn Enterprises LP showing insider buyingJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn

Jan 16, 2026

Jan 15, 2026

Resistance Check: Does Verastem Inc outperform in volatile markets2025 Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn

Jan 15, 2026

Jan 14, 2026

Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus

Jan 14, 2026

Jan 14, 2026

Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock - MarketBeat

Jan 14, 2026

Jan 13, 2026

EPS Watch: Why Verastem Inc stock is trending among retail tradersTrade Risk Assessment & Reliable Entry Point Alerts - Bộ Nội Vụ

Jan 13, 2026

Jan 12, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Chartmill

Jan 12, 2026

Jan 09, 2026

Polar Capital Holdings Plc Increases Stake in Verastem Inc - GuruFocus

Jan 09, 2026

Jan 09, 2026

Verastem, Inc. (VSTM) Investor Outlook: Biotech Stock With Over 100% Potential Upside - DirectorsTalk Interviews

Jan 09, 2026

Jan 08, 2026

Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда

Jan 08, 2026

Jan 08, 2026

Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - Улправда

Jan 08, 2026

Jan 08, 2026

Verastem updates oncology strategy in new corporate presentation - TipRanks

Jan 08, 2026

Jan 08, 2026

RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - marketscreener.com

Jan 08, 2026

Jan 07, 2026

Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha

Jan 07, 2026

Jan 07, 2026

Verastem (NASDAQ:VSTM) Shares Up 19.3%Should You Buy? - MarketBeat

Jan 07, 2026

Jan 05, 2026

Verastem shifts focus to KRAS G12D and pancreatic programs - MSN

Jan 05, 2026

Jan 04, 2026

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN

Jan 04, 2026

Jan 02, 2026

What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga

Jan 02, 2026

Jan 02, 2026

Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN

Jan 02, 2026

Jan 02, 2026

Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN

Jan 02, 2026

Dec 31, 2025

Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada

Dec 31, 2025

Dec 31, 2025

Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks

Dec 31, 2025

Dec 31, 2025

Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter

Dec 31, 2025

Dec 30, 2025

Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus

Dec 30, 2025

Dec 30, 2025

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha

Dec 30, 2025

Dec 30, 2025

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech

Dec 30, 2025

Dec 30, 2025

Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat

Dec 30, 2025

Dec 30, 2025

Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Dec 30, 2025

Dec 30, 2025

Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus

Dec 30, 2025

Dec 29, 2025

Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa

Dec 29, 2025

Dec 29, 2025

Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com

Dec 29, 2025

Dec 29, 2025

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits

Dec 29, 2025

Dec 29, 2025

Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - marketscreener.com

Dec 29, 2025

Dec 29, 2025

Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria

Dec 29, 2025

Dec 29, 2025

Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus

Dec 29, 2025

Dec 29, 2025

Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com

Dec 29, 2025

Dec 29, 2025

Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada

Dec 29, 2025

Dec 29, 2025

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire

Dec 29, 2025

Dec 29, 2025

Calkins, Verastem CFO, sells $628 in shares - Investing.com India

Dec 29, 2025

Dec 26, 2025

Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily

Dec 26, 2025

Dec 26, 2025

Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛

Dec 26, 2025